Live
FierceBiotechCaribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3CellDNA repair drives cisplatin-induced neuronal deathCellLong-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humansCellPersistent and transient senescent cells contribute to brain-barrier developmentCellContinuous modeling of primate embryogenesis from totipotency to early organogenesisCellRNA structure programs endogenous ADAR for precise and efficient editingFierceBiotech‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEOFierceBiotechTakeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdownEndpoints NewsTakeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3Endpoints NewsNeion Bio raises $23M Series A to make proteins from chicken eggsBioPharma DiveTakeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testClinical OMICsApp-Controlled “Wound Zipper” Aids Bespoke Skin Healing
BioWorld Nov 27, 2025

Gluetacs Therapeutics divulges new protein degradation inducers

Gluetacs Therapeutics divulges new protein degradation inducers

Original
Body unavailable. Use the original source.